Promising outcomes were observed with delanzomib, as it demonstrated the ability to induce apoptosis and inhibit RANKL-induced osteoclastogenesis in both MM (MM) cell lines and cells obtained from patients. Here, TNFSF11 is linked to Miyoshi myopathy.